Loading
Growing a patient's pancreatic tumour as mini-organs in a dish and testing chemotherapies on them to pick the regimen most likely to work.
Tuveson (CSHL) and others established PDAC organoids with transcriptomic signatures predicting FOLFIRINOX versus gemcitabine sensitivity (Tiriac 2018). Prospective trials (e.g., PASS-01, HOPE) test organoid- or signature-guided first-line choice. Turnaround (~4-6 weeks) and take rate (~70%) are the practical limits; the GATA6 classical/basal-like signature is a faster proxy.
Endoscopic biopsy or resection tissue grown in Matrigel with defined factors; dose-response to drugs read by viability assays.
Query for this technology: (TITLE:"PDAC organoid pharmacotyping" OR ABSTRACT:"PDAC organoid pharmacotyping") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PDAC organoid pharmacotyping, not a curated reading list.
Shares Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico.
Shares Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico.
Shares David A. Tuveson, Cold Spring Harbor Laboratory, Patient-derived organoids, Pancreatic ductal adenocarcinoma.
Shares Ex vivo drug sensitivity screening in blood cancers (EXALT), Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Ex vivo drug sensitivity screening in blood cancers (EXALT), Functional (ex vivo) drug testing.